Insilico Medicine
Insilico Medicine raises additional $37M in Series E extension to advance AI-discovered drug pipeline.
valuation undisclosed
Sources (1)
- Insilico Medicine news — Insilico Medicine primary
SovereignBio
Where the money moves in AI-biotech — the IPOs, partnerships, funding rounds and acquisitions building the field, placed on a timeline with the geopolitics (US · China · Japan · Korea · EU) that shape them. Every dollar figure links to its primary source — an SEC filing, an investor-relations page, or a company announcement. Nothing is installed; nothing about you is collected.
This is the tool. Figures are drawn only from free public sources (no PitchBook / Crunchbase paid feeds), so the picture is deliberately partial — see the coverage gauge below. Editorial is CC BY 4.0; each figure carries its own citation. A native version, when it ships, adds offline use; it never gates the web.
≈60%
Honest coverage: ≈60% of public activity
Built from free public sources, SovereignBio captures roughly 60% of AI-biotech capital activity. We show what we can source and name what we can’t, so you can calibrate your conclusions. As of 2026-06-10.
What’s covered
- US-listed IPOs (SEC S-1 / 424 filings)
- Major announced partnerships with disclosed economics
- Funding rounds disclosed via press release
- Public M&A announcements
Known gaps
- Undisclosed private rounds (most pre-Series-B)
- Confidential pharma BD deals without press release
- Most China-domestic rounds with CN-only filings
- Private valuations between funding events
- Stealth-mode companies pre-launch
Tracked capital by year $788M across 5 events
Data table
| Year | Tracked capital (USD) |
|---|---|
| 2020 | $232M |
| 2021 | $436M |
| 2024 | $120M |
Region
Sector
Type
5 of 5 events
-
Series E $37M -
Partnership $45M Isomorphic Labs
Isomorphic Labs / Eli Lilly drug-discovery partnership: $45M upfront, up to $1.7B in milestones.
with Eli Lilly · $45M upfront · up to $1.7B milestones
Sources (1)
- Isomorphic Labs news — Isomorphic Labs primary
-
Partnership $38M Isomorphic Labs
Isomorphic Labs / Novartis drug-discovery partnership: $37.5M upfront, up to $1.2B in milestones.
with Novartis · $38M upfront · up to $1.2B milestones
Sources (1)
- Isomorphic Labs news — Isomorphic Labs primary
-
IPO $436M Recursion Pharmaceuticals
Recursion Pharmaceuticals IPO on NASDAQ (RXRX), pricing 24M shares at $18.
NASDAQ · $18/share · 24M shares
Sources (1)
- Recursion Investor Relations — Recursion Pharmaceuticals, Inc. primary
-
IPO $232M Schrödinger
Schrödinger IPO on NASDAQ (SDGR): 13.66M shares at $17 including the over-allotment (11.88M base), ~$232M raised.
NASDAQ · $17/share · 13.66M shares
Sources (1)
- Schrödinger Investor Relations — Schrödinger, Inc. primary
No events match these filters.